Johnson & Johnson (JNJ), Tuesday announced that the U.S. Food and Drug Administration has approved supplemental New Drug Application or sNDA for Spravato, a monotherapy for adults with treatment-resistant depression, a psychiatric disorder.
The approval is supported by the company's study, which met its primary endpoint in four weeks, and showed a rapid and superior improvement in depressive symptoms, compared to placebo as early as 24 hours.
Moreover, the safety profile of Spravato, as a standalone treatment, was consistent with the existing body of clinical and real-world data.
In the pre-market hours, JNJ is trading at $147.28, up 0.17 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Health News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.